Recruiting Essential Tremor Studies in Irvine
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is character...
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain ...
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) o...
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to s...
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects...
Bevacizumab Treatment For Type 1 ROP
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Als...
Regeneron AA Multicenter (Dupilumab)
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affe...
Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP....
About Essential Tremor Clinical Trials in Irvine
Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.
There are currently 8 essential tremor clinical trials recruiting participants in Irvine, CA. These studies are seeking a combined 1,660 participants. Research is being sponsored by AbbVie, NRG Oncology, Karyopharm Therapeutics Inc and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Essential Tremor Clinical Trials in Irvine — FAQ
Are there essential tremor clinical trials in Irvine?
Yes, there are 8 essential tremor clinical trials currently recruiting in Irvine, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Irvine?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Irvine research site will contact you about next steps.
Are clinical trials in Irvine free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Irvine studies also compensate for your time and travel.
What essential tremor treatments are being tested?
The 8 active trials in Irvine are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.
Data updated March 2, 2026 from ClinicalTrials.gov